Zydus Cadila Gets First Patch Approval Amid Push Into US
Executive Summary
A generic rival to Novartis’ Exelon extended-release treatment for dementia marks Zydus Cadila’s first transdermal patch approval in the US, furthering the Indian firm’s strategy of targeting more complex delivery forms.
You may also be interested in...
Zydus Ready For Moraiya Reinspection In June
Zydus says its Moraiya plant should be ready for re-inspection at the end of June 2020, following a recent FDA warning letter. Meanwhile, as returns from levorphanol fall on the back of increased competition, the firm has written down investment by $37.5m causing Q2 profits to slump 74%. Post successful Phase II trials in the US for NASH and NAFLD indications, its hopes are now pinned on saroglitazar magnesium.
Levorphanol Write-Down Dents Zydus in Q2 But Saroglitazar Expectations Build
As returns from levorphanol fall on the back of increased competition, Zydus Cadila writes down investment by $37.5m causing Q2 profits to slump 74%. Post successful Phase II trials in the US for NASH and NAFLD indications, its hopes are now pinned on saroglitazar magnesium.
Analysts See More Headwinds For India’s Zydus Cadila After Quarterly Earnings Slide
Analysts said more challenges lie ahead for Zydus Cadila that will hobble earnings growth over the next couple of years, after the Indian firm reported a more than 20% slide in quarterly profit.